Literature DB >> 3037926

Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks.

D S Charney, S W Woods, W K Goodman, G R Heninger.   

Abstract

The effects of yohimbine, an alpha 2-adrenergic receptor antagonist, on anxiety, blood pressure, heart rate, and plasma levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) and cortisol were determined in 20 healthy subjects and 68 patients who had agoraphobia with panic attacks or panic disorder. Yohimbine produced panic attacks meeting DSM-III criteria in 37 patients and one healthy subject. The patients reporting yohimbine-induced panic attacks had significantly larger increases in plasma MHPG, cortisol, systolic blood pressure, and heart rate than the healthy subjects. These findings support the hypothesis relating high noradrenergic neuronal activity to the pathophysiology of panic attacks in a subgroup of panic disorder patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037926     DOI: 10.1176/ajp.144.8.1030

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  44 in total

1.  Modest neuropsychological deficits caused by reduced noradrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gene.

Authors:  K Kobayashi; Y Noda; N Matsushita; K Nishii; H Sawada; T Nagatsu; D Nakahara; R Fukabori; Y Yasoshima; T Yamamoto; M Miura; M Kano; T Mamiya; Y Miyamoto; T Nabeshima
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

2.  Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation.

Authors:  Marieke Soeter; Merel Kindt
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

3.  Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.

Authors:  John C Umhau; Melanie L Schwandt; Julie Usala; Christopher Geyer; Erick Singley; David T George; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

4.  Yohimbine bioavailability in humans.

Authors:  S K Guthrie; M Hariharan; L J Grunhaus
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy.

Authors:  Michael Davis; Karyn M Myers; Jasmeer Chhatwal; Kerry J Ressler
Journal:  NeuroRx       Date:  2006-01

6.  Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder.

Authors:  D S Charney; R B Innis; R S Duman; S W Woods; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 7.  Genetic animal models of anxiety.

Authors:  Deborah A Finn; Mark T Rutledge-Gorman; John C Crabbe
Journal:  Neurogenetics       Date:  2003-03-29       Impact factor: 2.660

8.  Educating psychiatrists for the 1990s.

Authors:  H Pardes
Journal:  Acad Psychiatry       Date:  1989-03

9.  A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

Authors:  W S Redfern; A Williams
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 10.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.